Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2020 16:01 ET | Source: Assertio Therapeutics, Inc.

Assertio to Present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020

LAKE FOREST, Ill., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that President, chief...
November 06, 2020 06:00 ET | Source: Assertio Therapeutics, Inc.

Assertio Reports Third Quarter 2020 Financial Results

Reported Net Product Sales of $34.3 Million Non-GAAP Net Product Sales of $33.7 Million; Increased 21.4% over Pro-Forma Second Quarter 2020 Non-GAAP Net Product Sales...
October 23, 2020 08:00 ET | Source: Assertio Therapeutics, Inc.

Assertio to Release Third Quarter 2020 Financial Results and Host Webcast on November 6, 2020

LAKE FOREST, Ill., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its third...
September 09, 2020 06:02 ET | Source: Assertio Therapeutics, Inc.

Assertio to Present at Cantor Virtual Global Healthcare Conference on September 16, 2020

LAKE FOREST, Ill., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, announced that the company will...
August 07, 2020 06:02 ET | Source: Assertio Therapeutics, Inc.

Assertio Reports Second Quarter 2020 Financial Results

--Completed all merger and integration activities in Q2----Repaid $10 million of Senior Secured Notes ahead of schedule-- --Zyla products partially contributed to Q2 net product sales of $20.2...
July 20, 2020 06:02 ET | Source: Assertio Therapeutics, Inc.

Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020

LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020...
May 11, 2020 08:00 ET | Source: Assertio Therapeutics, Inc.

Assertio Therapeutics Announces First-Quarter 2020 Results

-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger...
April 20, 2020 17:08 ET | Source: Assertio Therapeutics, Inc.

Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus

Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First...
April 08, 2020 16:05 ET | Source: Assertio Therapeutics, Inc.

Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024

LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender...
March 16, 2020 18:45 ET | Source: Assertio Therapeutics, Inc.

Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue...